Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data

Cytochrome P450 3A4 mRNA Is a More Reliable Marker than CYP3A4 Activity for Detecting Pregnane X Receptor-Activated Induction of Drug-Metabolizing Enzymes

(2010) O. A. Fahmi et al.   DRUG METABOLISM AND DISPOSITION

Evaluation of models for predicting drug–drug interactions due to induction

(2010) Odette A Fahmi et al.   Expert Opinion on Drug Metabolism & Toxicology

Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis

(2010) Debra M Meyer et al.   Journal of Inflammation-London

Calcineurin-Inhibitor-Free Immunosuppression Based on the JAK Inhibitor CP-690,550: A Pilot Study inDe NovoKidney Allograft Recipients

(2009) S. Busque et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial

(2009) J H Coombs et al.   ANNALS OF THE RHEUMATIC DISEASES

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

(2009) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

Guide to Receptors and Channels (GRAC), 4th edition

(2009)   BRITISH JOURNAL OF PHARMACOLOGY

Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Pharmacologic Effect of CP-690,550 in Patients With Psoriasis

(2009) Mary G. Boy et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY